{"id":"NCT01702298","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)","officialTitle":"An Open-label Study to Assess the Safety and Tolerability of MK-0431D for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12-07","primaryCompletion":"2013-05-29","completion":"2013-05-29","firstPosted":"2012-10-08","resultsPosted":"2014-05-30","lastUpdate":"2018-08-24"},"enrollment":42,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sitagliptin 100 mg/simvastatin 40 mg FDC","otherNames":["MK-0431D"]},{"type":"DRUG","name":"Metformin","otherNames":["Fortamet®","Glucophage®","Glucophage® XR","Glumetza®","Riomet®","Metgluco®","Glycoran®"]}],"arms":[{"label":"Sitagliptin 100 mg/simvastatin 40 mg FDC","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to examine the safety and tolerability of sitagliptin 100 mg/simvastatin 40 mg FDC (MK-0431D) in Vietnamese participants with type 2 diabetes mellitus with inadequate glycemic control on metformin.","primaryOutcome":{"measure":"Change From Baseline in Fasting Plasma Glucose (FPG)","timeFrame":"Baseline and Week 6","effectByArm":[{"arm":"Sitagliptin 100 mg/Simvastatin 40 mg FDC","deltaMin":-27.6,"sd":58.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":22},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":42},"commonTop":["Hypoglycemia"]}}